Detalhe da pesquisa
1.
No NFATC2 fusion in simple bone cyst of the jaw.
Histopathology
; 83(2): 326-329, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36939112
2.
A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target.
Lab Invest
; 102(4): 391-400, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921235
3.
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial).
BMC Cancer
; 22(1): 629, 2022 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35672690
4.
NTRK fusions are extremely rare in bone tumours.
Histopathology
; 79(5): 880-885, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34148257
5.
Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression.
Int J Mol Sci
; 22(12)2021 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34200964
6.
A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation.
Mod Pathol
; 33(3): 404-419, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31383960
7.
Soft tissue aneurysmal bone cyst: six new cases with imaging details, molecular pathology, and review of the literature.
Skeletal Radiol
; 48(7): 1059-1067, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30603771
8.
Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers.
Lab Invest
; 98(1): 41-50, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29155424
9.
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Br J Cancer
; 118(8): 1074-1083, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29576625
10.
Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand?
Pharmacol Res
; 137: 193-204, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30316903
11.
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Cancer Immunol Immunother
; 66(1): 119-128, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27853827
12.
Osteosarcoma Stem Cells Have Active Wnt/ß-catenin and Overexpress SOX2 and KLF4.
J Cell Physiol
; 231(4): 876-86, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26332365
13.
Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.
Lab Invest
; 96(10): 1128-37, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27617402
14.
Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.
Br J Cancer
; 114(11): 1219-26, 2016 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27140314
15.
Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.
Mod Pathol
; 29(9): 1028-37, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27312065
16.
No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.
BMC Cancer
; 16: 475, 2016 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27418340
17.
Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.
J Pathol
; 236(3): 348-59, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25757065
18.
High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.
Blood
; 131(18): 2086-2089, 2018 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29514783
19.
Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor.
Int J Cancer
; 133(11): 2512-21, 2013 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23436697
20.
CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
Cancer
; 119(20): 3696-702, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23913621